ERBB2 and breast cancer: Considering the outstanding results that this class of drugs has obtained in HER2+ BC, mainly with the use of trastuzumab emtansine (T-DM1) [57] and trastuzumab deruxtecan (T-Dxd) [58], the search for targetable molecules in TNBC has led to the development of sacituzumab govitecan (SG), an ADC targeting trophoblast cell-surface antigen-2 (Trop-2) conjugated via a cleavable linker to the active metabolite of irinotecan (SN-38).